Patients with diabetes mellitus (DM), especially those treated with insulin,1,2 undergoing contemporary percutaneous coronary intervention (PCI) with drug-eluting stents (DES) are at an increased risk for adverse ischemic events including myocardial infarction (MI), stent thrombosis, and restenosis, as well as both cardiac and noncardiac death.3, 4, 5, 6 Patients with DM comprise 20% to 30% of the population undergoing PCI,6,7 and as the prevalence of DM continues to rise,8 the relative safety and efficacy of novel DES should be evaluated in this high-risk population. This evidence concerns the gene INS and myocardial infarction.